Company logo

BION - BB Biotech AG

SIX -> Healthcare -> Biotechnology
Kusnacht, Switzerland
Type: Equity

BION price evolution
BION
(in millions $) 29 Jun 2021 30 Mar 2021 30 Dec 2020 29 Sep 2020
Current assets
Cash $1.03 $1.03 $2.29 $2.29
Short term investments
Net receivables $14.17 $14.17 $19.34 $19.34
Inventory
Total current assets $15.2 $15.2 $21.62 $21.62
Long term investments
Property, plant & equipment $96.63 $96.63 $93.54 $93.54
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $112.53 $112.53 $115.88 $115.88
Current liabilities
Accounts payable $94.96 $94.96 $89.04 $89.04
Deferred revenue
Short long term debt $2.59 $2.59 $2.59 $2.59
Total current liabilities $119.36 $119.36 $112.76 $112.76
Long term debt $56.69 $56.69 $59.02 $59.02
Total noncurrent liabilities
Total debt
Total liabilities $183.7 $183.7 $177.58 $177.58
Shareholders' equity
Retained earnings -$134.08 -$134.08 -$124.69 -$124.69
Other shareholder equity -$6.69 -$6.69 -$6.61 -$6.61
Total shareholder equity -$71.32 -$71.32 -$61.84 -$61.84
(in millions $) 29 Apr 2022 30 Dec 2020 30 Dec 2019 30 Dec 2018
Current assets
Cash $0.01 $2.29 $0.08 $0.47
Short term investments
Net receivables $5.47 $19.34 $77.11 $56.81
Inventory
Total current assets $5.48 $21.62 $77.2 $57.28
Long term investments
Property, plant & equipment $93.54 $49.54 $41.64
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $5.48 $115.88 $127.52 $99.75
Current liabilities
Accounts payable $89.04 $35.78 $13.8
Deferred revenue
Short long term debt $2.59 $5.76 $7.69
Total current liabilities $3.12 $112.76 $69.91 $40.17
Long term debt $0.78 $59.02 $1.01 $7.86
Total noncurrent liabilities
Total debt
Total liabilities $3.9 $177.58 $77.46 $48.53
Shareholders' equity
Retained earnings -$73.12 -$124.69 -$4.45 -$3.35
Other shareholder equity -$0.23 -$6.61 -$6.71 -$6.53
Total shareholder equity $1.58 -$61.84 $49.89 $51.17
(in millions $) 29 Jun 2021 30 Mar 2021 30 Dec 2020 29 Sep 2020
Revenue
Total revenue $0.28 $0.28 $38.23 $38.23
Cost of revenue $2.08 $2.08 $35.46 $35.46
Gross Profit -$1.8 -$1.8 $2.77 $2.77
Operating activities
Research & development
Selling, general & administrative $2.53 $2.53 $64.06 $64.06
Total operating expenses $4.6 $4.6 $98.76 $98.76
Operating income -$4.32 -$4.32 -$60.53 -$60.53
Income from continuing operations
EBIT -$4.32 -$4.32 -$60.53 -$60.53
Income tax expense $0.66 $0.66
Interest expense -$1.12 -$1.12 -$1.09 -$1.09
Net income
Net income -$4.7 -$4.7 -$59.43 -$59.43
Income (for common shares) -$4.7 -$4.7 -$59.43 -$59.43
(in millions $) 29 Apr 2022 30 Dec 2020 30 Dec 2019 30 Dec 2018
Revenue
Total revenue $1.2 $103.67 $24.06 $1.54
Cost of revenue $5.85 $97.41 $21.01 $3.01
Gross Profit -$4.65 $6.26 $3.05 -$1.47
Operating activities
Research & development
Selling, general & administrative $61.45 $132.2 $8.84 $7.94
Total operating expenses $65.23 $228.01 $29.84 $10.94
Operating income -$64.03 -$124.34 -$5.77 -$9.4
Income from continuing operations
EBIT -$64.03 -$124.34 -$5.77 -$9.4
Income tax expense $1.31 $1.18 $0.01
Interest expense -$2.92 -$2.78 -$1.8 -$1.57
Net income
Net income -$64.51 -$121.55 -$0.19 -$10.93
Income (for common shares) -$64.51 -$121.55 -$0.19 -$10.93
(in millions $) 29 Jun 2021 30 Mar 2021 30 Dec 2020 29 Sep 2020
Net income -$4.7 -$4.7 -$59.43 -$59.43
Operating activities
Depreciation $1.15 $1.15 $0.69 $0.69
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $2.24 $2.24 -$2.47 -$2.47
Investing activities
Capital expenditures -$2.57 -$2.57 -$17.63 -$17.63
Investments
Total cash flows from investing -$2.57 -$2.57 -$17.67 -$17.67
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings -$0.26 -$0.26 $21.19 $21.19
Total cash flows from financing -$0.26 -$0.26 $21.19 $21.19
Effect of exchange rate -$0.04 -$0.04 -$0.06 -$0.06
Change in cash and equivalents -$0.63 -$0.63 $0.98 $0.98
(in millions $) 29 Apr 2022 30 Dec 2020 30 Dec 2019 30 Dec 2018
Net income -$64.51 -$121.55 -$0.19 -$10.93
Operating activities
Depreciation $3.5 $2.77 $2.8 $1.38
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $41.84 -$12.9 $0.38 -$9.67
Investing activities
Capital expenditures -$4.56 -$36.44 -$5.43 -$5.4
Investments
Total cash flows from investing -$4.56 -$36.4 -$5.43 -$5.4
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings -$44.86 $51.41 $4.85 $1.37
Total cash flows from financing -$40.76 $51.41 $4.85 $15.05
Effect of exchange rate $1.76 $0.1 -$0.18 $0.31
Change in cash and equivalents -$1.71 $2.21 -$0.39 $0.3
News
After layoffs, Molecular Templates overhauls C-suite
American City Business Journals 4 Aug 2023
3 Stocks Insiders Are Buying
Benzinga via Yahoo Finance 22 Sep 2021
3 Stocks Insiders Are Buying
Benzinga via Yahoo Finance 12 Sep 2021
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue $77.01M
EBITDA -$126.02M
EBIT -$129.70M
Net Income -$128.25M
Revenue Q/Q -97.97%
Revenue Y/Y 56.00%
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA -112.30%
ROE 192.63%
Debt/Equity 2.47
Net debt/EBITDA -1.45
Current ratio 0.13
Quick ratio N/A